FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065070940> ?p ?o ?g. }

• W2065070940 endingPage "4532" @default.
• W2065070940 startingPage "4531" @default.
• W2065070940 abstract "A common feature of Pseudomonas aeruginosa chronic respiratory infections (CRI), including those occurring in patients suffering from cystic fibrosis, bronchiectasis, or chronic obstructive pulmonary disease, is a very high prevalence (30 to 60%) of hypermutable (or mutator) strains deficient in the DNA mismatch repair (MMR) system, in contrast to what is observed in acute processes (<1%) (1, 4, 10, 13, 14). The presence of hypermutable strains has been found to be linked to the high antibiotic resistance rates of P. aeruginosa clinical isolates recovered from patients with CRI (1, 10, 13), and in vitro and in vivo experiments have shown that hypermutation dramatically speeds up resistance development during exposure to antimicrobial agents (15, 16).Colistin has reemerged in the last decade as a relevant therapeutic option for the treatment of infections caused by multidrug-resistant gram-negative bacteria (8). The objective of this work was to assess the activity of this antibiotic against hypermutable P. aeruginosa strains isolated from patients with CRI. Colistin susceptibility was determined by the Etest method, recently shown to be reliable for this purpose (3), in a collection of 97 P. aeruginosa isolates characterized in two previous studies (9, 10). This collection included one to four isolates recovered between 2003 and 2004 from each of 51 patients suffering from cystic fibrosis (n = 21), bronchiectasis (n = 22), or chronic obstructive pulmonary disease (n = 8). Each patient was shown to be chronically infected by a different P. aeruginosa clone, and of the 97 isolates, 43 were found to be hypermutable (most of them defective in the MMR gene mutS); a marked association between hypermutation and multidrug resistance was also documented when susceptibility to the commonly used antipseudomonal agents ceftazidime, imipenem, meropenem, ciprofloxacin, and tobramycin was analyzed in this collection (7, 8). Finally, a collection of 50 P. aeruginosa clinical isolates recovered from 50 patients admitted to our intensive care unit (ICU) between 2002 and 2003 was also tested for comparative purposes. None of these isolates was hypermutable, and each of them belonged to a different clonal type, as documented in a previous study (4). P. aeruginosa strain ATCC 27853 was used for quality control, yielding an MIC of 1 μg/ml, which falls within the acceptable range defined by the Clinical and Laboratory Standards Institute.The distribution of the colistin MICs obtained for the hypermutable and nonhypermutable isolates from patients with CRI and the nonhypermutable isolates from ICU patients is shown in Fig. ​Fig.1.1. In contrast to what was previously documented for other antimicrobial agents, MICs tended to be highest for ICU isolates (geometric mean MIC, 2.0 μg/ml) and lowest for hypermutable isolates from patients with CRI (0.48 μg/ml). Nonhypermutable isolates from patients with CRI showed an intermediate distribution of MICs (geometric mean MIC, 0.92 μg/ml). For only one of the strains (from the ICU isolate group) did the MICs surpass the currently recommended susceptibility breakpoint (≤4 μg/ml) (6). Statistical analysis (Mann-Whitney U test) of the distribution of the MICs yielded significant differences (P < 0.001) when hypermutable and nonhypermutable isolates from patients with CRI were compared; statistically significant differences (P < 0.001) were also obtained when nonhypermutable isolates from ICU and CRI patients were analyzed. Increased colistin susceptibility of the hypermutable strains was not likely a direct consequence of the inactivation of the MMR system since the MICs for reference strain PAO1 and its mutS-deficient derivative PAOΔmutS (15) were found to be essentially identical (2 μg/ml).FIG. 1.Distribution of the MICs of colistin for hypermutable P. aeruginosa strains isolated from patients with CRI (n = 43), nonhypermutable P. aeruginosa strains isolated from patients with CRI (n = 54), and nonhypermutable P. aeruginosa strains ...It is noteworthy that almost none of the patients had ever been treated with colistin (which was only seldom used in our hospital until very recently), and therefore the documented distributions are expected to reflect those naturally occurring in the absence of the selective pressure exerted by antimicrobial therapy. It is known that P. aeruginosa undergoes an intense genetic adaptation process during the establishment of CRI, in which mutations leading to the loss of function of multiple genes are positively selected (17). Whereas hypermutation may favor the persistence of CRI by facilitating the acquisition of adaptive mutations, natural hypermutable strains often end up showing reduced in vitro and in vivo fitness, probably due to the unavoidable accumulation of deleterious mutations for secondary environments (7, 11, 12). Whether the observed colistin-hypersusceptibility of natural hypermutable strains is determined by the acquisition of particular adaptive mutations, such as those leading to the frequently modified lipopolysaccharide structure of CRI isolates (2, 5), or simply by the accumulation of deleterious mutations remains to be elucidated. Although results from this work would certainly argue in favor of the use of colistin for attempting to counterselect hypermutable strains in CRI, they should be taken cautiously, since development of resistance to this agent under selective pressure is not unexpected (6), although in vitro experiments have suggested that it may occur to a lesser extent compared with other antipseudomonal agents (15)." @default.
• W2065070940 created "2016-06-24" @default.
• W2065070940 creator A5000378072 @default.
• W2065070940 creator A5013937606 @default.
• W2065070940 creator A5040575395 @default.
• W2065070940 creator A5048017496 @default.
• W2065070940 creator A5091254297 @default.
• W2065070940 date "2007-12-01" @default.
• W2065070940 modified "2023-10-18" @default.
• W2065070940 title "Increased Susceptibility to Colistin in Hypermutable <i>Pseudomonas aeruginosa</i> Strains from Chronic Respiratory Infections" @default.
• W2065070940 cites W1967023708 @default.
• W2065070940 cites W1972847233 @default.
• W2065070940 cites W1979152503 @default.
• W2065070940 cites W1985687704 @default.
• W2065070940 cites W1993513102 @default.
• W2065070940 cites W2030529701 @default.
• W2065070940 cites W2102614752 @default.
• W2065070940 cites W2102695300 @default.
• W2065070940 cites W2106355138 @default.
• W2065070940 cites W2114939043 @default.
• W2065070940 cites W2127170823 @default.
• W2065070940 cites W2128328795 @default.
• W2065070940 cites W2137761651 @default.
• W2065070940 cites W2141963202 @default.
• W2065070940 cites W2146761052 @default.
• W2065070940 cites W2164032940 @default.
• W2065070940 cites W2169053394 @default.
• W2065070940 doi "https://doi.org/10.1128/aac.00981-07" @default.
• W2065070940 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2168005" @default.
• W2065070940 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17893154" @default.
• W2065070940 hasPublicationYear "2007" @default.
• W2065070940 type Work @default.
• W2065070940 sameAs 2065070940 @default.
• W2065070940 citedByCount "8" @default.
• W2065070940 countsByYear W20650709402014 @default.
• W2065070940 countsByYear W20650709402015 @default.
• W2065070940 crossrefType "journal-article" @default.
• W2065070940 hasAuthorship W2065070940A5000378072 @default.
• W2065070940 hasAuthorship W2065070940A5013937606 @default.
• W2065070940 hasAuthorship W2065070940A5040575395 @default.
• W2065070940 hasAuthorship W2065070940A5048017496 @default.
• W2065070940 hasAuthorship W2065070940A5091254297 @default.
• W2065070940 hasBestOaLocation W20650709401 @default.
• W2065070940 hasConcept C2777637488 @default.
• W2065070940 hasConcept C2779259085 @default.
• W2065070940 hasConcept C501593827 @default.
• W2065070940 hasConcept C523546767 @default.
• W2065070940 hasConcept C54355233 @default.
• W2065070940 hasConcept C71924100 @default.
• W2065070940 hasConcept C86803240 @default.
• W2065070940 hasConcept C89423630 @default.
• W2065070940 hasConceptScore W2065070940C2777637488 @default.
• W2065070940 hasConceptScore W2065070940C2779259085 @default.
• W2065070940 hasConceptScore W2065070940C501593827 @default.
• W2065070940 hasConceptScore W2065070940C523546767 @default.
• W2065070940 hasConceptScore W2065070940C54355233 @default.
• W2065070940 hasConceptScore W2065070940C71924100 @default.
• W2065070940 hasConceptScore W2065070940C86803240 @default.
• W2065070940 hasConceptScore W2065070940C89423630 @default.
• W2065070940 hasIssue "12" @default.
• W2065070940 hasLocation W20650709401 @default.
• W2065070940 hasLocation W20650709402 @default.
• W2065070940 hasLocation W20650709403 @default.
• W2065070940 hasLocation W20650709404 @default.
• W2065070940 hasOpenAccess W2065070940 @default.
• W2065070940 hasPrimaryLocation W20650709401 @default.
• W2065070940 hasRelatedWork W1969134509 @default.
• W2065070940 hasRelatedWork W2155899797 @default.
• W2065070940 hasRelatedWork W2197362931 @default.
• W2065070940 hasRelatedWork W2266621686 @default.
• W2065070940 hasRelatedWork W2603651488 @default.
• W2065070940 hasRelatedWork W2994858082 @default.
• W2065070940 hasRelatedWork W3004106354 @default.
• W2065070940 hasRelatedWork W3011185416 @default.
• W2065070940 hasRelatedWork W3195518430 @default.
• W2065070940 hasRelatedWork W4312065371 @default.
• W2065070940 hasVolume "51" @default.
• W2065070940 isParatext "false" @default.
• W2065070940 isRetracted "false" @default.
• W2065070940 magId "2065070940" @default.
• W2065070940 workType "article" @default.